Quantcast

Latest Trastuzumab Stories

2011-12-08 22:34:34

Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight.

2011-12-08 22:31:56

A large, multicenter, randomized study has shown that obese patients with HER2-positive breast cancer have larger tumors, increased lymph node involvement and, when not treated with trastuzumab, poorer long-term outcomes than normal-weight patients.

2011-12-08 12:55:30

Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant.

2011-12-08 12:53:09

Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo.

2011-12-07 14:36:01

One study presented at the meeting, which is being held in Budapest, Hungary, 7 to 10 December, reports on an initiative using echocardiography to document early warning signs of adverse effects from trastuzumab (Herceptin ®)¹, while the other uses echocardiography to evaluate the protective role of ACE inhibitors and statins on the hearts of cancer patients².

2011-12-01 19:03:26

Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin® (trastuzumab).


Word of the Day
marcescent
  • Withering but not falling off, as a blossom that persists on a twig after flowering.
The word 'marcescent' comes from a Latin word meaning 'to wither'.
Related